Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Signed informed consent~* Men and women aged between 40 and 85 years (inclusive)~* Body mass index \< 35 kg/m2~* Ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study~Exclusion criteria (any of the following):~* Known hypersensitivity to the study drug or any excipients of the drug formulation~* Treatment with another investigational drug within 3 weeks prior to screening~* History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug~* Severe renal failure (glomerula filtration rate \< 30 ml/min)~* Moderately or severe impaired left ventricular function (ejection fraction \< 40%)~* Moderately or severe impaired right ventricular function~* Systolic pulmonary pressure \> 45 mmHg~* Acute or recent (\<7 days) myocardial infarction~* Child bearing potential

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Heme arginate (high dose) (Type: EXPERIMENTAL): 24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
- Heme arginate (low dose) (Type: EXPERIMENTAL): 24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
- Placebo (Type: PLACEBO_COMPARATOR): 24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).